Seventy years ago, on the day Wenceslaus and Denicia Billiot got married, their wedding party danced along a road that ran from one end of Isle de Jean Charles to the other.
Each year, environmental pollutants cost an estimated 1.7 million lives among children under 5, according to World Health Organization reports released Monday.
A meeting Friday afternoon between President Trump and Ohio Gov. John Kasich, his former rival in the GOP primaries, had no set agenda. But Kasich came armed with one anyway: his hope to blunt drastic changes to the nation’s health-care system envisioned by some conservatives in Washington.
Over the past few years, researchers have identified some of the machinery involved in regulating these marks. Each requires a writer to place it, an eraser to remove it and a reader to interpret it. As the identities of these proteins emerged, scientists have come to understand that m6A affects not only RNA splicing, but also translation and RNA stability.
Global funding for research on neglected diseases — which include tuberculosis, HIV/AIDS and malaria — is at its lowest level since 2007, according to the annual G-FINDER investment report by Policy Cures Research, a health-policy analysis firm in Sydney, Australia.
Yesterday, at a meeting here organized by the Smithsonian Initiative on Biodiversity Genomics and the Shenzhen, China–based sequencing powerhouse BGI, a small group of researchers upped the ante even more, announcing their intent to, eventually, sequence “all life on Earth.”
Overall, 23 of the scientists (roughly 8% of sanctioned researchers) received NIH funding after receiving an ORI sanction. Of that group, 17 researchers won more than $101 million for 61 new projects. Thirteen continued to receive funding from NIH grants that had been awarded before being sanctioned.
As the science grew even more compelling and venture capital (VC) beckoned, the jockeying to start CRISPR companies became intense. The research community was rent apart by concerns about intellectual property, academic credit, Nobel Prize dreams, geography, media coverage, egos, personal profit, and loyalty. A billion dollars poured into what might be called CRISPR Inc.
Rather than wait years for treatments to be approved by federal officials, many of them are testing ways to modify human biology that fall somewhere on the spectrum between science and entrepreneurialism. It’s called biohacking, and it’s one of the biggest things happening in the Bay Area.
Now, 22 teams of computer scientists have unveiled a set of algorithms able to predict the odor of different molecules based on their chemical structure. It remains to be seen how broadly useful such programs will be, but one hope is that such algorithms may help fragrancemakers and food producers design new odorants with precisely tailored scents.
The New York Times
The Broad Institute in Cambridge, Mass., will retain potentially lucrative rights to a powerful gene-editing technique that could lead to major advances in medicine and agriculture, the federal Patent and Trademark Office ruled on Wednesday.
An old steroid treatment, long available outside the United States, received approval this week for a rare disease that afflicts about 15,000 Americans. Though not previously approved in the United States, the drug, deflazacort, has for years been available to patients suffering from the devastating and fatal disease Duchenne muscular dystrophy; families can import it from abroad for about $1,200 per year on average. The new list price for the drug? $89,000 a year.
Los Angeles Times
As with Trump’s proposed elimination of consumer safeguards, environmental-protection measures and financial reforms, the reality is that if his administration proceeds with a wholesale deregulation of the drug industry, the public will be largely undefended against the aggressive and potentially dangerous predations of multibillion-dollar conglomerates.
France’s government auditor has taken a sharp swipe at efforts to develop a science super-campus near Paris that, by 2020, was supposed to rival the world’s top campus universities, such as the US Massachusetts Institute of Technology (MIT). More than €5.3 billion (US$5.7 billion) in public spending has been earmarked for the Paris-Saclay science cluster, the Court of Auditors estimates in an annual report published on 8 February — but the original vision of creating a large integrated research university there is “at a standstill”.
Price now takes the helm of a $1 trillion government department that includes the National Institutes of Health (NIH), the Centers for Disease Control and Prevention, and the Food and Drug Administration (FDA). Most visibly, he will be charged with overseeing the repeal and replacement of the Affordable Care Act, also known as Obamacare, that Republicans have promised.
A group backed by the Bill & Melinda Gates Foundation that works on India’s immunization program will now be funded by the health ministry, a government official said, a move in part prompted by fears foreign donors could influence policy making.
Legislators in Hawaii are trying to ban the sale of sunscreens that contain two UV-filtering chemicals, after studies suggested that they harm coral reefs.
The U.S. Department of Agriculture (USDA) today removed public access to tens of thousands of reports that document the numbers of animals kept by research labs, companies, zoos, circuses, and animal transporters—and whether those animals are being treated humanely under the Animal Welfare Act. Henceforth, those wanting access to the information will need to file a Freedom of Information Act request.
Los Angeles Times
Donald Trump will be coming into office waving the banner of deregulation. While most of the speculation about his plans has focused on the financial industry and the possibility of eviscerating Dodd-Frank reforms, keep your eyes on the Food and Drug Administration. In a Trump administration the agency, figuratively speaking, will have a big bull’s-eye on its back.
Some fear a demonstration led by researchers might only serve to paint scientists as an interest group, further politicizing scientific issues. And at least one veteran science lobbyist has urged organizers to make sure it’s a march for science, not scientists.
By studying the insects under more-natural conditions, scientists hope to better understand how to eradicate them — and malaria — using an emerging genetic-engineering technology called gene drives. The technique can quickly disseminate genetic modifications in wild populations through an organism’s offspring, prompting some activists to call for it to be shelved. Yet gene drives might not be as effective as activists think. Recent research has identified a major hurdle to using them to eliminate diseases and vanquish invasive pests: evolution.
Kaveh Daneshvar was thrilled when he was invited to speak at a molecular biology meeting next month in Banff, Canada. Daneshvar, a molecular geneticist, is finishing a postdoc at Harvard Medical School and Massachusetts General Hospital in Boston and preparing to go on the job market. He hoped that the conference talk would give him much-needed exposure to leaders in his field.
Clearly, private companies cannot be expected to invest on their own. But it is incumbent on governments to invest, and thus address this market failure, in partnership with pharma. It is therefore encouraging that there is now a solid plan to do just that: the Coalition for Epidemic Preparedness Innovations (CEPI), launched on 18 January at the World Economic Forum in Davos, Switzerland, aims to develop and take through early clinical trials vaccines against potential threats. It already has enough cash to work on three — MERS, Nipah-virus infection and Lassa fever.
In 1950, Japan’s scientific community, chastened by the complicity of researchers in their nation’s disastrous military adventurism, took an extraordinary vow. “To preserve our integrity as scientists, we express our firm commitment both domestically and abroad that we will never pursue scientific research for the purpose of war,” declared the Science Council of Japan (SCJ), now the nation’s equivalent to the U.S. National Academies of Sciences, Engineering, and Medicine.
Growing functional human tissues and organs would provide much needed material for regeneration and repair. New technologies are taking us in that direction. In addition to their use in regenerative medicine, stem cells that grow and morph into organ-like structures known as organoids can be used in drug development and toxicology testing. The potential developments and possibilities are numerous and affect not only biomedicine but also areas of ongoing ethical debate.
The WHO lost a lot of trust in the aftermath of the 2014 Ebola outbreak in West Africa. Nabarro said his hope is to make sure that doesn’t happen again.
The practical implications of Trump’s action on Friday are harder to decipher. Its language instructs all federal agencies to “waive, defer, grant exemptions from or delay” any part of the law that imposes a financial or regulatory burden on those affected by it. That would cover consumers, doctors, hospitals and other providers, as well as insurers and drug companies.